AbbVie (ABBV) Net Income - Minority (2020 - 2021)
AbbVie (ABBV) reported Net Income - Minority of -$25.0 million for Q2 2021, down 4.17% year-over-year from -$26.1 million in Q2 2020, and down 8.7% on a QoQ basis from -$23.0 million in Q1 2021.
AbbVie (ABBV) has 2 years of Net Income - Minority data on file, last reported at -$25.0 million in Q2 2021.
- Quarterly Net Income - Minority fell 4.17% year-over-year to -$25.0 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was -$25.0 million (down 4.17% YoY) and the FY2020 annual result came in at -$21.0 million, changed N/A from the prior year.
- Net Income - Minority eased to -$25.0 million in Q2 2021 per ABBV's latest filing, from -$23.0 million in the prior quarter.
- Across five years, Net Income - Minority topped out at -$19.0 million in Q3 2020 and bottomed at -$25.0 million in Q2 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -25.00 Mn |
| Mar 31, 2021 | -23.00 Mn |
| Dec 31, 2020 | -21.00 Mn |
| Sep 30, 2020 | -19.00 Mn |
| Jun 30, 2020 | -24.00 Mn |